Table 2.
Patient, tumor, and treatment characteristics
| Characteristic | n or median (% or range) |
|---|---|
| Cohort size | 27 |
| Age at treatment, years | 68 (26-94) |
| Sex | |
| Female | 14 (52%) |
| Male | 13 (48%) |
| KPS | |
| 100 | 7 (26%) |
| 90 | 11 (41%) |
| 80 | 4 (15%) |
| 70 | 5 (19%) |
| <70 | 0 |
| Histology | |
| UPS | 6 (22%) |
| Spindle cell neoplasm, NOS | 4 (15%) |
| Leiomyosarcoma | 3 (11%) |
| Synovial sarcoma | 3 (11%) |
| Undifferentiated spindle cell sarcoma | 2 (7%) |
| Myxofibrosarcoma | 2 (7%) |
| Myxoid sarcoma | 1 (4%) |
| Atypical spindle cell lipomatous tumor | 1 (4%) |
| Fibroblastic sarcoma | 1 (4%) |
| Extraskeletal Ewing sarcoma | 1 (4%) |
| Extraskeletal osteosarcoma | 1 (4%) |
| PEComa | 1 (4%) |
| Angiosarcoma | 1 (4%) |
| Histology Grouped | |
| UPS/Spindle cell sarcoma | 12 (44%) |
| Leiomyosarcoma | 3 (11%) |
| Synovial sarcoma | 3 (11%) |
| Liposarcoma | 1 (4%) |
| Angiosarcoma | 1 (4%) |
| Other | 7 (26%) |
| Location | |
| Extremity | 16 (59%) |
| Head and neck | 1 (4%) |
| Trunk | 4 (15%) |
| Lung | 4 (15%) |
| Abdomen/pelvis | 2 (7%) |
| Clinical tumor size, cm | 7.0 (1.2-21.0) |
| Clinical tumor size group* | |
| ≤5 cm | 10 (37%) |
| >5 cm to 10 cm | 7 (26%) |
| >10 cm to 15 cm | 5 (19%) |
| ≥15 cm | 5 (19%) |
| Tumor grade | |
| 1 | 3 (11%) |
| 2 | 5 (19%) |
| 3 | 19 (70%) |
| Clinical prognostic stage group | |
| IA | 0 |
| IB | 1 (4%) |
| II | 2 (7%) |
| IIIA | 4 (15%) |
| IIIB | 1 (4%) |
| IV | 19 (70%) |
| Distantly metastatic | |
| Yes | 19 (70%) |
| No | 8 (30%) |
| Lesion type treated | |
| Untreated primary | 10 (37%) |
| Locally recurrent disease | 4 (15%) |
| Prior resection | 10 (37%) |
| Prior resection plus RT | 3 (11%) |
| Metastasis | |
| Systemic therapy timing related to RT | |
| None | 9 (33%) |
| Neoadjuvant | 7 (26%) |
| Neoadjuvant + concurrent | 3 (11%) |
| Neoadjuvant + concurrent + adjuvant | 1 (4%) |
| Neoadjuvant + adjuvant | 2 (7%) |
| Concurrent | 3 (11%) |
| Concurrent + adjuvant | 1 (4%) |
| Adjuvant | 1 (4%) |
| Concurrent systemic therapy regimen | |
| Ifosfamide | 6 (15%) |
| Paclitaxel | 1 (4%) |
| Pazopanib | 1 (4%) |
| RT Regimen | |
| 66/55/50.6 Regimen | 9 (33%) |
| 60/50/46 Regimen | 18 (67%) |
Abbreviations: KPS = Karnofsky performance status scale; NOS = not otherwise specified; PEComa = malignant perivascular epithelioid cell neoplasm; RT = radiation therapy; UPS = undifferentiated pleomorphic sarcoma.
⁎
Clinical tumor size group represents the tumors of interest divided into categories based upon T staging criteria.